| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 1.4 | 1.1 |
| Gross profit | 0.8 | 0.5 |
| Net income | -2.7 | -3.0 |
| EPS (diluted, $ a share) | $-0.86 | $-3.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +25.2% |
|---|---|
| Gross margin | 54.5% |
| Operating margin | -192.7% |
10-Q filed with the SEC, NASDAQ: INBS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Intelligent Bio Solutions Inc.: key numbers
- Share price
- $1.50Close, Nov 16
- Market cap
- $4.98M
- Shares outstanding
- 3.32MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Intelligent Bio Solutions Inc.
All →Intelligent Bio Solutions Financial Results
Intelligent Bio Solutions reported record fiscal first quarter 2027 revenue of $1.39 million, a 25% increase year-over-year, driven by higher-margin cartridge sales. The company also achieved a significant regulatory milestone by submitting its FDA 510(k) premarket notification for its fingerprinting drug screening system, targeting the U.S. market.
- Term
- Q1 2027
“Fiscal first quarter revenue was the highest quarterly revenue in our Company’s history. Each reader draws on a recurring supply of higher-margin cartridges, which is driving most of our revenue growth. Our business continues to scale with improving unit economics, including expanding gross profit margins driven by manufacturing efficiencies and a higher share of revenue from higher-margin cartridge consumables.”
Harry Simeonidis, President and CEO
“In September, we submitted our 510(k) premarket notification to the FDA for the Intelligent Fingerprinting Drug Screening System, the culmination of the clinical program we executed throughout 2026 and a key step toward our planned entry into the multi-billion-dollar U.S. drug screening market. Going forward, we will continue to invest in the clinical and regulatory work behind our 510(k) submission while maintaining discipline across the rest of the business.”
Harry Simeonidis, President and CEO
Intelligent Bio Solutions Investor Presentation
Intelligent Bio Solutions Inc. has furnished a formal investor presentation relating to its business and operations. Additionally, the company's Board of Directors adopted amended and restated bylaws to clarify stockholder voting procedures, specifically regarding the treatment of abstentions and broker non-votes.
Intelligent Bio Solutions Business Update
Intelligent Bio Solutions Inc. provided an update on its total shares outstanding, which reached 3,316,803 shares as of September 10, 2026. The increase resulted from the exercise of pre-funded warrants for 285,000 shares and the issuance of 4,333 restricted shares under an existing advisory agreement.